Cybin is trading up 5.35% now at $12.41, as biotechnology shares rally broadly on positive mRNA cancer-vaccine trial news.
- No fresh company-specific announcement dated August 20, 2026 was identified.
- Recent optimism also follows Cybin’s August 3 appointment of Michael Halstead as CEO, which coverage linked to the stock’s earlier rally.
- The company’s August 18 appointments were supportive but appear secondary to today’s sector-wide strength.